Health
A Twice-a-Year Shot Could Transform HIV Prevention — but England’s NHS Won’t Fund It Yet
NICE has declined to recommend Gilead’s lenacapavir for HIV prevention, calling it poor value for money — a decision HIV charities call a missed opportunity.
